Zinc Acetate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Zinc Acetate: Severe nonproliferative diabetic retinopathy
One-Sentence Summary
Zinc acetate is a zinc salt originally used for conditions such as Wilson disease, dermatitis, burns and iron metabolism disorders. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but no clinical trials and no publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (8 of 8) – CDSCO approval status is not included in this data |
| Number of Listed Products | 8 (valid: 8) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, zinc acetate is a zinc salt used in Wilson disease and in several skin and wound conditions, and mechanistically it may be applicable to diabetic retinopathy.
A plausible but unproven link is zinc’s role as a cofactor for antioxidant enzymes such as Cu/Zn-superoxide dismutase. Through this role it may influence oxidative stress and inflammation in the retina. Zinc is also involved in glucose metabolism and microvascular health, which is relevant to diabetic eye disease.
These links are hypotheses only. Nothing in the data compiled for this report confirms them. The same model also ranks the broader term “diabetic retinopathy” highly (score 0.9992), which is consistent with the first prediction but is not independent evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 47176 | Coverdoz 50mg/100mg/12mg Kit | Kit (box of 1) | Not stated in the records |
| 246747 | Ziverdo Kit | Kit (box of 1) | Not stated in the records |
| 247671 | Zincovec 50 Tablet | Tablet (strip of 10) | Not stated in the records |
| 105716 | HI ZN Syrup | Syrup (60 ml bottle) | Not stated in the records |
| 248054 | Zia Syrup | Syrup (100 ml bottle) | Not stated in the records |
All 8 registrations are valid products, and none is cancelled. Only the first 5 are shown above.
Review correction (2026-11-06): Originally stated: “All 8 registrations are valid single-ingredient products, and none is cancelled.” Removed: it described the products as single-ingredient or combination products in a way that did not match the Indian medicine data (the Indian Medicine Dataset as of 2026-11-06). Source: Indian Medicine Dataset.
Safety Considerations
- Contraindications (knowledge graph, not label text): The knowledge graph links zinc acetate to inherited porphyria, porphyrin metabolism disease and porphyria as contraindicated conditions.
- Drug Interactions: The interaction screen returned 100 records, and the 20 reviewed show mostly minor interactions. Moderate-level interactions were noted with:
- Alendronic acid
- Risedronic acid
- Ibandronate
- Tetracycline
- Baloxavir marboxil
Minor interactions include several corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone) and immunosuppressive or biologic agents (abatacept, adalimumab, azathioprine, among others).
Please refer to the package insert for further safety information, including warnings.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there are no clinical trials or publications for diabetic retinopathy, so the evidence level is L5 (model prediction only). The mechanism of action is also not available, and the package insert safety data has not been obtained.
To proceed, the following is needed:
- Mechanism of action data for zinc acetate (e.g., from DrugBank)
- Package insert warnings and contraindications from the India regulatory records, which are required before any safety screening
- A systematic literature search on zinc and diabetic retinopathy, including preclinical and observational studies
- A check of clinical trial registries for zinc in diabetic retinopathy
- Assessment of route and formulation suitability for retinal disease, since the marketed forms are oral tablets, syrups and kits
- Review of the porphyria contraindication signal and of interactions with chelation-sensitive drugs (bisphosphonates, tetracycline)
Review Log
Below is the review log for this page: statements checked against official Indian medicine data (the Indian Medicine Dataset used by this site). Corrections are limited to basic factual statements; model predictions, evidence levels, and conclusions were not rewritten.
| Review date | Item | Action | Source |
|---|---|---|---|
| 2026-11-06 | Removed: “single-ingredient” | Corrected | Indian Medicine Dataset |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.